Back to Results
First PageMeta Content
Health / Autoimmune diseases / Biotechnology / Arthritis / Monoclonal antibodies / Rheumatoid arthritis / Autoimmunity / Humanized antibody / Biomarker / Anatomy / Medicine / Immunology


Press release[removed]24_SuppreMol IL-3 License_final
Add to Reading List

Document Date: 2012-08-10 12:02:08

Open Document

File Size: 56,78 KB

Share Result on Facebook

City

Munich / Martinsried / /

Company

Bayerische Patentallianz GmbH / BioMedPartners AG / Contact SuppreMol GmbH / SuppreMol GmbH / Santo Holding GmbH / Bayern Kapital GmbH / FCP Biotech Holding GmbH / KfW Mittelstandsbank / /

Country

Germany / /

Currency

EUR / /

/

Event

Funding / Business Partnership / /

Facility

laboratory of Prof. Dr. Robert Huber / Further building / University of Regensburg / University Hospital of Regensburg / Regensburg University Hospital / Max Planck Institute / /

IndustryTerm

biopharmaceutical / /

MedicalCondition

allergies / disease / further preclinical programs targeting autoimmune diseases / arthritis / Rheumatoid Arthritis / autoimmune disease / Primary Immune Thrombocytopenia / inflammation / autoimmune diseases / /

Organization

University of Regensburg / German Federal Ministry of Education / Max Planck Society / University Hospital of Regensburg / Max Planck Institute for Biochemistry / Regensburg University Hospital / /

Person

Matthias Mack / Peter Buckel / Peter Sondermann / /

/

Position

autoimmune disease specialist / CEO / Professor / co-founder / Chief Executive Officer / member of Scientific Advisory Board / /

Product

Fc / SM401 / Fc gamma receptor platform / /

Technology

alpha / /

URL

www.suppremol.com / /

SocialTag